Afinitor (Everolimus)

Afinitor (everolimus) is a kinase inhibitor used for the treatment of:

• Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
• Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced, or metastatic
  Limitations of Use: Afinitor is not indicated for the treatment of patients with functional carcinoid tumors
• Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
• Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery

Recommended Dosage:

• Hormone Receptor-Positive, HER2-Negative Breast Cancer: The recommended dosage of Everolimus is 10 mg orally once daily until there is evidence of disease progression or unacceptable toxicity.
• Neuroendocrine Tumors (NET): The recommended dosage of Everolimus is 10 mg orally once daily until there is evidence of disease progression or unacceptable toxicity.
• Renal Cell Carcinoma (RCC): The recommended dosage of Everolimus is 10 mg orally once daily until there is evidence of disease progression or unacceptable toxicity.
• Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma: The recommended dosage of Everolimus is 10 mg orally once daily until there is evidence of disease progression or unacceptable toxicity.
• Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA): The recommended starting dosage of Everolimus is 4.5 mg/m2 orally once daily until there is evidence of disease progression or unacceptable toxicity.
• Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures: The recommended starting dosage of Everolimus is 5 mg/m2 orally once daily until there is evidence of disease progression or unacceptable toxicit

• Everolimus may cause non-infectious pneumonitis, a potentially serious condition. Patients should be monitored for symptoms such as coughing, shortness of breath, or chest pain. If symptoms appear, evaluate promptly. Dose adjustment or discontinuation may be necessary based on the severity of lung symptoms.
• Everolimus can increase susceptibility to bacterial, fungal, and viral infections. Serious or fatal infections may occur. Patients should be closely monitored for signs of infection. Interrupting treatment or dose reduction may be required if infections become severe or do not respond to standard therapy.
• Everolimus may trigger severe hypersensitivity reactions, including rash, fever, and swelling. Discontinue treatment immediately if symptoms of allergic reaction develop. Patients with known hypersensitivity to rapamycin derivatives should not take this drug. Medical supervision is essential for managing allergic responses.
• Concomitant use of Everolimus with ACE inhibitors may lead to angioedema. Symptoms include facial swelling, difficulty breathing, and throat tightness. Discontinue Everolimus and ACE inhibitors immediately if angioedema occurs, and seek emergency care. Monitor patients closely when both medications are used together.
  Stomatitis, including mouth ulcers and soreness, is a common side effect of Everolimus. Maintain good oral hygiene and use alcohol-free mouthwashes. Severe cases may require dose interruptions or treatment. Inform healthcare providers if oral pain, redness, or swelling becomes uncomfortable or worsens.
• Everolimus can impair kidney function, especially in patients with existing kidney issues or when used with nephrotoxic drugs. Monitor serum creatinine and urine output regularly. Dose adjustments or discontinuation may be necessary if signs of acute kidney injury or renal failure occur.
• Everolimus may delay wound healing after surgery or injury. Patients should avoid undergoing major surgeries while on treatment, if possible. Monitor surgical sites for infection or poor healing. Temporarily discontinue Everolimus before and after surgery based on the doctor’s recommendations.
• Everolimus can cause hyperglycemia, hyperlipidemia, and hypertriglyceridemia. Regularly monitor blood glucose, cholesterol, and lipid levels. Patients with diabetes or high cholesterol should be managed carefully. Adjust treatment or introduce supportive therapies to address persistent metabolic imbalances during Everolimus therapy.
• Everolimus can suppress bone marrow activity, leading to low levels of white blood cells, red blood cells, or platelets. Perform regular complete blood counts. Patients experiencing severe myelosuppression may need dose reduction or interruption. Monitor for signs of anemia, infection, or bleeding.
• Everolimus may harm an unborn baby. Women of childbearing potential should use effective contraception during treatment and for eight weeks after stopping the drug. If pregnancy occurs, inform the healthcare provider immediately. Everolimus should only be used during pregnancy if absolutely necessary.
• Everolimus may pass into breast milk and could harm a nursing infant. Women should not breastfeed while taking Everolimus and for at least two weeks after the last dose. Discuss breastfeeding alternatives with a healthcare professional to ensure the infant's safety.

What documents are required to import Afinitor to India?

Afinitor (Everolimus) tablets can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is Afinitor available in India?

Afinitor (Everolimus tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Afinitor in India (Mumbai, Kolkata,
• Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada,
• Europe, and Australia
• Ensuring 100% transparency.

Afinitor can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of Afinitor (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Afinitor 2.5 mg, 5 mg, 7.5 mg, and 10 mg Tablet price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source Afinitor (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Afinitor®?

Everolimus is a Generic Name for the trade name drug Afinitor®.

What is the Manufacturer's Name of Afinitor®?

Afinitor® is manufactured by Novartis Pharmaceuticals Corporation.

Is Afinitor approved by the FDA?

Yes, Afinitor® is approved by the FDA. Date of first approval: March 30, 2009.

What is the dosage and form of Afinitor® supplied?

Afinitor is supplied for tablets: 2.5 mg, 5 mg, 7.5 mg, and 10 mg for oral administration.

What are the most common side effects of Afinitor® 2.5 mg, 5 mg, 7.5 mg, and 10 mg Tablets?

The most common side effects of Afinitor® tablets are stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache, and decreased appetite.

How much does Afinitor® 2.5 mg, 5 mg, 7.5 mg, and 10 mg Tablet cost in India?

Prices of Afinitor Tablets may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Afinitor 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Afinitor® 2.5 mg, 5 mg, 7.5 mg, and 10 mg Tablets be available in SAARC countries?

Apart from Gulf countries, Afinitor® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Afinitor® Tablets in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Afinitor® 2.5 mg, 5 mg, 7.5 mg, and 10 mg Tablets online in India?

Yes, one can buy Afinitor 2.5 mg, 5 mg, 7.5 mg, and 10 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Afinitor® Tablets through legal channels.

What are the storage conditions of Afinitor® 2.5 mg, 5 mg, 7.5 mg, and 10 mg Tablets?

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Store in the original container, protect from light and moisture.